Inozyme Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical firm, announced that CEO Axel Bolte will present at two investor conferences. The first is the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 7:40 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, with a prerecorded presentation available on-demand starting May 24, 2022, at 7 a.m. ET. Replays can be accessed from Inozyme's Investor Relations section on their website, emphasizing its commitment to developing therapeutics for rare diseases linked to mineralization.

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the following investor conferences:

• The Bank of America Securities 2022 Healthcare Conference. The presentation will take place on Tuesday, May 10, 2022, at 7:40 p.m. ET/4:40 p.m. PT.
• The H.C. Wainwright Global Investment Conference. The prerecorded presentation will become available on-demand starting Tuesday, May 24, 2022, at 7 a.m. ET.

A replay of the presentations can be accessed from the Investor Relations section of Inozyme’s website under events and will be available for a limited time following the events.

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
stefan.riley@inozyme.com        

Media:
SmithSolve
Matt Pera
973-886-9150
matt.pera@smithsolve.com

FAQ

What is Inozyme Pharma's upcoming conference presentation schedule for May 2022?

Inozyme Pharma will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 7:40 p.m. ET and at the H.C. Wainwright Global Investment Conference on May 24, 2022, with a prerecorded presentation available.

Where can I find the replay of Inozyme Pharma's presentations?

Replays of Inozyme Pharma's presentations will be available in the Investor Relations section of their website after the events.

What therapeutic area is Inozyme Pharma focusing on?

Inozyme Pharma is developing therapies for rare diseases associated with abnormal mineralization, particularly focusing on conditions caused by defects in the ENPP1 and ABCC6 genes.

What is the status of Inozyme Pharma's lead therapeutic candidate, INZ-701?

INZ-701 is currently in Phase 1/2 clinical trials for treating ENPP1 and ABCC6 Deficiencies.

Who is presenting for Inozyme Pharma at the investor conferences?

Axel Bolte, the co-founder, president, and CEO of Inozyme Pharma, will be presenting.